WA

Waters Corporation

WATHealthcareNASDAQ

Diagnostics & Research

PriceMA150MA200
Loading chart…
End-of-day data · ScananceOpen live chart on TradingView ↗
Indicator snapshot · Today
Premium
Today's indicator reading is locked

Free plan shows historical signals only. Upgrade to see this ticker's current MA150, MA200, RSI, and MACD readings.

Upgrade to see today →
Financials · Annual
Revenue
$3.17B
+7.0% YoY
Net Income
$642.6M
+0.8% YoY
EBITDA
$1.03B
-0.6% YoY
Free Cash Flow
-$142.1M

Scan Results

Daily timeframe
DateIndicatorDetails
Aug 25 MACD Negative CrossoverHistogram -0.5116, negative momentum
Aug 24CONFIRMED MACD Negative CrossoverHistogram -0.3317, negative momentum
RSI OverboughtRSI 70.3, above 70, stock may be overbought
About Waters Corporation

Part of the healthcare sector, Waters Corporation (WAT) is listed under Diagnostics & Research. Valued at $39.56B, WAT is a large-cap name in its sector. The company operates through two segments, Waters and TA.

Where WAT stands vs its 150-day and 200-day moving averages

As of the August 25, 2026 close, WAT finished 17.50% above its 150-day moving average ($349.56) and 14.36% above its 200-day moving average ($359.18). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.

Is WAT overbought or oversold?

At the August 25, 2026 close, WAT's RSI(14) was 60.9, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.

Key stats
Market Cap$39.56B
P/E (TTM)102.52
Fwd P/E24.35
EPS$3.93
Beta1.19
52W Change+39.7%
ROE1.9%
Analysis

The company holds $539.0M in cash, though total debt stands at $5.48B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. Free cash flow is running at -$142.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of 1.9% points to modest capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.97B (2022) to $3.17B (2025).

Debt significantly exceeds cash reserves, which means the company's financial flexibility could be constrained during economic downturns. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. At over 50x earnings, WAT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Waters Corporation and its sector.

Links
More Healthcare stocks
Browse all stocks →
Not financial advice. Scanance shows end-of-day technical indicators (not real-time prices) for information only. Results can be wrong; past performance does not guarantee future results.PrivacyTerms